When the WTP threshold was $41,511/QALY, the probability of SUG-CAP being cost-effective compared with PLA-CAP for the first-line treatment of advanced G/GEJ adenocarcinoma with PD-L1 CPS ≥5 was 0%. Here, CD274 is linked to gastroesophageal junction adenocarcinoma.